Fenbendazole and Berberine for the Treatment of Lymphoma

The anthelminthic drug fenbendazole destroys microtubules in cancer cells and inhibits cell growth by interfering with their ability to metabolize sugar. It also boosts production of p53, a gene that keeps cancer cells from growing unchecked. Adding Berberine to the mix further limits cancer cells’ ability to take up glucose and starves them of the energy they need to grow. Fenbendazole and Berberine have been gaining interest lately due to several cancer success stories involving the use of this deworming medication along with other supplements.

During facility treatment for pinworms (Apiculuris tetraptera) at our institution, established human lymphoma xenografts failed to grow in C.B-17/Icr-prkdcscid/Crl SCID mice. The experiment was designed to determine whether a sterilizable diet supplemented with fenbendazole, supplemental vitamins, or both affected tumor development in this model.

Twenty vendor-supplied 4-wk-old SCID mice were divided into 4 groups: control, fenbendazole plus standard diet, supplemental vitamin-only group, and fenbendazole plus supplemental vitamins plus standard diet. Initial complete blood counts were similar for all groups and demonstrated a low white cell count with a paucity of lymphocytes. However, at study termination, terminal total white cell and neutrophil values were significantly lower (P = 0.001 and P 0.04) in the fenbendazole plus vitamin group compared with controls.  sanare lab fenbendazole